Compare PZG & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PZG | ONCY |
|---|---|---|
| Founded | 1992 | 1998 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Metal Mining | Pharmaceuticals and Biotechnology |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 92.5M | 106.1M |
| IPO Year | 1999 | 1999 |
| Metric | PZG | ONCY |
|---|---|---|
| Price | $1.19 | $0.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | ★ 784.7K | 669.1K |
| Earning Date | 11-14-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.31 | $0.33 |
| 52 Week High | $1.41 | $1.51 |
| Indicator | PZG | ONCY |
|---|---|---|
| Relative Strength Index (RSI) | 54.35 | 48.10 |
| Support Level | $1.13 | $0.92 |
| Resistance Level | $1.24 | $1.06 |
| Average True Range (ATR) | 0.07 | 0.07 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 57.86 | 64.65 |
Paramount Gold Nevada Corp is an exploration-stage mining company. Together with its subsidiaries, the company is engaged in the business of acquiring, exploring, and developing precious metal projects in the United States. Also, it explores for gold and silver. The company enhances the value of projects by implementing exploration and engineering programs that are likely to expand and upgrade known mineralized material to reserves. Its projects include sleeper gold, grassy mountain gold, frost project, other non-material, and others.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.